Connect with others who understand.

Sign up Log in
Resources
About MyAmyloidosisTeam
Powered By
Real members of MyAmyloidosisTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Trial NI0006 On ATTRwt Drug To Remove Amloid Fibrlis From Heart. Will This Remove Amloid From Muscles, Nerves And Spine Also?

A MyAmyloidosisTeam Member asked a question 💭
Chagrin Falls, OH

I have minor damage to heart but lost unexplained strength in left leg.

February 25
View reactions
A MyAmyloidosisTeam Member

Abstract
Background: Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the amelioration of cardiac dysfunction. NI006 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells.
Methods: In this phase 1, double-blind trial, we randomly assigned (in a 2:1 ratio) 40 patients with wild-type or variant ATTR cardiomyopathy and chronic heart failure to receive intravenous infusions of either NI006 or placebo every 4 weeks for 4 months. Patients were sequentially enrolled in six cohorts that received ascending doses (ranging from 0.3 to 60 mg per kilogram of body weight). After four infusions, patients were enrolled in an open-label extension phase in which they received eight infusions of NI006 with stepwise increases in the dose. The safety and pharmacokinetic profiles of NI006 were assessed, and cardiac imaging studies were performed.

Results: The use of NI006 was associated with no apparent drug-related serious adverse events. The pharmacokinetic profile of NI006 was consistent with that of an IgG antibody, and no antidrug antibodies were detected. At doses of at least 10 mg per kilogram, cardiac tracer uptake on scintigraphy and extracellular volume on cardiac magnetic resonance imaging, both of which are imaging-based surrogate markers of cardiac amyloid load, appeared to be reduced over a period of 12 months. The median N-terminal pro-B-type natriuretic peptide and troponin T levels also seemed to be reduced.

Conclusions: In this phase 1 trial of the recombinant human antibody NI006 for the treatment of patients with ATTR cardiomyopathy and heart failure, the use of NI006 was associated with no apparent drug-related serious adverse events. (Funded by Neurimmune; NI006-101 ClinicalTrials.gov number, NCT04360434.).

Copyright

March 13
A MyAmyloidosisTeam Member

I’m sure it would. Why can’t they push this through quickly like they did with the Covid vax? Now I want it!!!!

February 25

Related content

View All

I Am Wondering If I Should Continue To Take Tafamidis As I Am In Stage Iiib Advanced Heart Failure?

A MyAmyloidosisTeam Member asked a question 💭
Yuma, AZ

ATTRwt : Has Anyone Verified Hearth Thickness After Using Tafamidis By Echocardiogram Versus The Thickness Before The Therapy?

A MyAmyloidosisTeam Member asked a question 💭
Cernobbio, Italy

Do Any Of You Fellow ATTRwt Sufferers Have Ankle Nerve Problems?

A MyAmyloidosisTeam Member asked a question 💭
Greenwich, CT
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data Policy and Privacy policies.Your privacy is our priority Lock Icon
Already a Member? Log in